Biomarkers in Patients With Suspected HFpEF
Recruiting · NCT06101693 · Observational (researchers observe without assigning treatment) · Lead sponsor: NHS Greater Glasgow and Clyde
View the official record on ClinicalTrials.gov →Interventions studied
Plasma biomarker levels
What this trial is about
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1. alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity 2. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity. 3. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L 4. the prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L)
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Written informed consent
- Age ≥ 18 years
- NT-proBNP sample taken by primary care physician as part of routine care for suspected heart failure
Exclusion criteria
- Unable to consent to inclusion in study due to significant cognitive impairment
- Geographical/ social reasons preventing attending study centre
- Unable to complete study assessments
- Patients presenting with acute HF or a previous diagnosis of HF
Where it is running
3 locations listed.
- Glasgow Royal Infirmary - Glasgow, United Kingdom
- New Victoria Hospital - Glasgow, United Kingdom
- Queen Elizabeth University Hospital - Glasgow, United Kingdom